The Biomedical Advanced Research and Development Authority (BARDA) has awarded drug maker Summit Therapeutics $32 million over the next 2 years for development of a new antibiotic for Clostridium difficile infection (CDI).
A team of scientists in the United States and the United Kingdom have identified additional benefits in a new class of antibacterial compounds that specifically kill Clostridium difficile strains without disrupting beneficial bacteria in the gut, according to a study today in Science Translational Medicine.
Today the Saudi Arabian Ministry of Health (MOH) reported two new MERS-CoV cases in Dumah Al Jandal. At this time, it's not known if the new cases are related to a hospital outbreak in that city first reported at the beginning of August.
A study today involving 111 patients found that early fecal microbiota transplantation (FMT) dramatically improves survival in severe Clostridium difficile infections (CDIs).
The Saudi Arabian Ministry of Health (MOH) reported a new case of MERS-CoV today in a man from Medina.
The 67-year-old expatriate is in stable condition after presenting with symptoms of MERS-CoV (Middle East respiratory syndrome coronavirus). The man had indirect contact with camels. Indirect contact with camels, including drinking camel milk, is a known risk factor for the disease.
A retrospective analysis of antibiotic prescriptions in England published yesterday in the Journal of Antimicrobial Chemotherapy found that nearly 8% of all antibiotics dispensed in primary care are prescribed by non-medical prescribers (NMPs), mostly nurses.
Canadian researchers are reporting the first case of the drug-resistant fungal pathogen Candida auris in Canada.
A study yesterday in Antimicrobial Resistance and Infection Control found that patients with methicillin-resistant Staphylococcus aureus (MRSA) in Norway have longer hospital stays and incur higher costs than those without MRSA.
The sharp rise is independent of known C diff risk factors and occurred across all US regions.
The study appears to be the first to measure colonization incidence or infections as a primary outcome.
